Has IMPROVE-IT improved cardiovascular outcome?

Abstract

Get full access to this article

View all access options for this article.

References

Cannon

, Blazing

, Giugliano

. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–97. http://dx.doi.org/10.1056/NEJMoa1410489

SIGN Clinical Guideline 97. Risk estimation and the prevention of cardiovascular disease – A national clinical guideline February 2007. p. 28–35. http://www.sign.ac.uk/pdf/sign97.pdf (accessed 7/8/2015).

NICE Clinical Guideline 181. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. July 2014. https://www.nice.org.uk/guidance/cg181 (accessed 7/8/2015).

Davignon

. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39–43.

Baigent

, Keech

, Kearney

. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78. 6. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431–43. http://dx.doi.org/10.1056/NEJMoa0800742

Laufs

, Descamps

, Catapano

. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J 2014 Aug 7; 35: 1996–2000. http://dx.doi.org/10.1093/eurheartj/ehu228

Jarcho

, Keaney

. Proof that lower is better – LDL cholesterol and IMPROVE-IT. N Engl J Med 2015; 372: 2448–50. http://dx.doi.org/10.1056/NEJMe1507041